OVERVIEW - PIPELINE

Robust Development Pipeline & Partnerships

Programs

Oncology

MLL-Menin

(Leukemia)

Yap-Tead*

(Solid Tumors)

STING*

(Tumor Myeloid cells)

RAS*

(Protein Degradation)

Additional Programs

CLK

(Cancer & DMD)

LpxC

(Gram - Bacteria)

Collaboration

Cardiovascular

Oncology

Target

Identification

In-Silico

Pre-Optimization

Synthesis

Testing

Pre-IND

Studies

Lead

Identification

Lead

Optimization

IND

Potential

Market

2019

2021

 

2022

 

 

2022

 

 

 

2020

 

 

2021

$1B

$5B

$1B

$5B

$3B

$1B

Partnerships with Novartis and Proctor & Gamble to design drug candidates for cardiavascular and cancer targest

Our focus areas are unmet needs in oncology, drug resistant bacterial infections, and other life threatening diseases. The SCULPT platform enables a new way to approach these problems, opening the door for the development of novel medicines. 

 

A2A oncology programs apply our therapeutic design methodology towards inhibiting protein-protein interactions (PPIs). Pharmacological targets of this class have important roles in a range of cancer types, but have been traditionally challenging to inhibit. SCULPT enables the design of novel ligands specifically to match the unique topological features of this target class.

 

Targets for A2A antibiotic programs were selected based on their broad spectrum applicability to gram-negative bacterial species, as well as novelty to circumvent rapid target-associated resistance. A unique bioinformatic approach was incorporated into the SCULPT process to yield candidates with "antibiotic-like" properties, in order to maximize the chances of activity and minimize drug efflux.

menu
Contact

BioLabs New York
180 Varick Street
New York, NY 10014

​​

Cambridge Innovation Center
1 Broadway 
Cambridge, MA 02142
Boston

Info@Atoms2applications.com

© 2019 A2A Pharma. All rights reserved